On mice bearing PSMA‐positive prostate cancer xenografts, the biodistributions/dosimetry, tumor growth inhibition, and toxicities were evaluated for the same total injected radioactivity that was delivered by different split ratios between the two carriers. The gene discussed is FOLH1; the disease is Familial prostate cancer.